- Home
- RARE vs GSHD Comparison
RARE vs GSHD Comparison
Compare RARE & GSHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RARE | GSHD |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RARE | GSHD |
|---|---|---|
| Price | $23.86 | $63.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 11 |
| Target Price | $73.11 | ★ $95.73 |
| AVG Volume (30 Days) | ★ 2.7M | 254.5K |
| Earning Date | 02-13-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 68.12 |
| EPS | N/A | ★ 1.14 |
| Revenue | ★ $630,598,000.00 | $353,231,000.00 |
| Revenue This Year | $20.17 | $16.89 |
| Revenue Next Year | $19.10 | $18.89 |
| P/E Ratio | ★ N/A | $57.21 |
| Revenue Growth | 20.63 | ★ 25.01 |
| 52 Week Low | $18.41 | $59.53 |
| 52 Week High | $46.50 | $127.99 |
Technical Indicators
Market Signals| Indicator | RARE | GSHD |
|---|---|---|
| Relative Strength Index (RSI) | 41.45 | 38.81 |
| Support Level | $23.26 | $59.53 |
| Resistance Level | $25.82 | $69.67 |
| Average True Range (ATR) | 1.02 | 2.77 |
| MACD | 0.43 | -0.39 |
| Stochastic Oscillator | 48.69 | 31.02 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About GSHD Goosehead Insurance Inc.
Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions.